scholarly journals Acupuncture and related therapies for vasomotor symptoms in menopausal women: protocol of a systematic review and network meta-analysis

Author(s):  
Xia Chen ◽  
◽  
Yanji Zhang ◽  
Yingyue Rao ◽  
Yingrong Zhang ◽  
...  
2021 ◽  
Vol 12 ◽  
Author(s):  
Bethany D. Skinner ◽  
Rebecca J. Davies ◽  
Samuel R. Weaver ◽  
N. Tim Cable ◽  
Samuel J. E. Lucas ◽  
...  

Sex differences in cerebrovascular disease rates indicate a possible role for ovarian sex steroid hormones in cerebrovascular function. To synthesise and identify knowledge gaps, a systematic review and meta-analysis was conducted to assess how ovarian sex steroid hormone changes across the lifespan affect cerebrovascular function in women. Three databases (EMBASE, MEDLINE and Web of Science) were systematically searched for studies on adult cerebrovascular function and ovarian sex steroid hormones. Forty-five studies met pre-defined inclusion criteria. Studied hormone groups included hormone replacement therapy (HRT; n = 17), pregnancy (n = 12), menstrual cycle (n = 7), menopause (n = 5), oral contraception (n = 2), and ovarian hyperstimulation (n = 2). Outcome measures included pulsatility index (PI), cerebral blood flow/velocity (CBF), resistance index (RI), cerebral autoregulation, and cerebrovascular reactivity. Meta-analysis was carried out on HRT studies. PI significantly decreased [−0.05, 95% CI: (−0.10, −0.01); p = 0.01] in post-menopausal women undergoing HRT compared to post-menopausal women who were not, though there was considerable heterogeneity (I2 = 96.8%). No effects of HRT were seen in CBF (p = 0.24) or RI (p = 0.77). This review indicates that HRT improves PI in post-menopausal women. However, there remains insufficient evidence to determine how changing ovarian sex steroid hormone levels affects cerebrovascular function in women during other hormonal phases (e.g., pregnancy, oral contraception).


2016 ◽  
Vol 123 (11) ◽  
pp. 1735-1743 ◽  
Author(s):  
D Wei ◽  
Y Chen ◽  
C Wu ◽  
Q Wu ◽  
L Yao ◽  
...  

2020 ◽  
Vol 39 ◽  
pp. 101150
Author(s):  
Hanieh Salehi-Pourmehr ◽  
Alireza Ostadrahimi ◽  
Mehdi Ebrahimpour-Mirzarezaei ◽  
Azizeh Farshbaf-Khalili

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Emmanouil Bouras ◽  
Christopher Papandreou ◽  
Ioanna Tzoulaki ◽  
Konstantinos K. Tsilidis

AbstractPreclinical data suggest that endogenous sex steroid hormones may be implicated in colorectal cancer (CRC) development, however, findings from epidemiological studies are conflicting. The aim of this systematic review and meta-analysis was to investigate the associations between endogenous concentrations of sex hormones and CRC risk. PubMed and Scopus were searched until June 2020 for prospective studies evaluating the association between pre-diagnostic plasma/serum concentrations of estradiol, testosterone and sex-hormone binding globulin (SHBG) and CRC risk. Summary relative risks (RRs) and 95% confidence intervals (CIs) were estimated using the inverse-variance weighted random-effects model based on the DerSimonian-Laird estimator. Eight studies were included in the meta-analysis after evaluating 3,859 non-duplicate records. Four of the eight studies had a nested case–control design, one study was a case-cohort and the rest three studies were cohort studies, and they included on average 295 cases (range:48–732) and 2,105 controls. No associations were found for endogenous sex steroid hormones in men or post-menopausal women with CRC risk, with evidence for substantial heterogeneity observed among women. Findings from this meta-analysis do not support presence of associations between pre-diagnostic concentrations of testosterone, estradiol and SHBG with incident CRC risk in men and post-menopausal women.


Sign in / Sign up

Export Citation Format

Share Document